Static lung hyperinflation is an independent risk factor for lung cancer in patients with chronic obstructive pulmonary disease

Zamarrón, Ester; Prats, Eva; Tejero, Elena; Pardo, Paloma; Galera, Raúl; Casitas, Raquel; Martínez‐Cerón, Elisabet; Romera, D.; Oriol, Ana Jaureguízar; García‐Río, Francisco

doi:10.1016/j.lungcan.2018.12.012

Cited by 14 publications

(9 citation statements)

References 64 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Primary bronchial LC: (1) the patient's personal data such as age, gender, tissue type, TNM staging, degree of tissue differentiation, and clinical pathological data were complete; (2) all postoperative pathological specimens of the patients were diagnosed as LC by pathologists; and (3) according to the WHO International Histological Classification Standards [16], the staging was carried out. Exclusion criteria: (1) patients with uncontrollable heart disease such as heart failure (congestive) and acute myocardial ischemia; (2) those who are pregnant and lactating; (3) those with uncontrollable liver and kidney function; (4) those who had received antitumor therapy (within 2 months); ( 5) people with mental illness; (6) people who were allergic to iodine or arsenic; (7) people with severe esophageal varices; and (8) people who did not cooperate with treatment or were discharged automatically.…”

Section: Inclusion Criteria and Exclusionmentioning

confidence: 99%

“…According to pathological characteristics, non-small-cell LC can be divided into squamous cell carcinoma, adenocarcinoma, adenosquamous carcinoma, and large-cell carcinoma. Among them, lung adenocarcinoma has the highest incidence, accounting for about 50% of all LC [7][8][9]. Surgical treatment is the first choice for early and midterm NSCLC.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Study on Serum miR-204 Expression Levels in Patients with Severe Pneumonia and Patients with Primary Bronchial Lung Cancer and Its Diagnostic Value

Zheng¹,

Huang

2021

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

Objective. To analyze the expression and clinical significance of miR-204 in the serum of patients with severe pneumonia (SP) and primary bronchial lung cancer (LC). Methods. 65 SP patients and 43 primary bronchial LC patients who were treated in the hospital from January 2017 to December 2018 were randomly selected as the SP group and LC group. At the same time, healthy patients from the physical examination department of the hospital were selected. 65 cases were the control group. QRT-PCR detected serum miR-204 expression and compared the differences between groups. The pathological data of patients were collected, and the relationship between serum miR-204 and the patient’s pathological data was compared; the area under the ROC curve and Kaplan–Meier curve were used to evaluate the diagnostic value of serum miR-204 for the two conditions and to explore the relationship between serum miR-204 and prognosis. Results. The serum miR-204 of the SP group was (0.43 ± 0.09), the serum miR-204 of the LC group was (0.40 ± 0.10), the serum miR-204 of the control group was (1.00 ± 0.09), and the miR-204 level of was significantly higher than that of the control group, and the difference between the groups was statistically significant ( P < 0.05). There was no significant difference in serum miR-204 levels between the SP group and the LC group ( P > 0.05). Serum miR-204 levels in SP patients with cumulative organs ≥3 were higher than those with cumulative organs <3, and the difference was statistically significant ( P < 0.001). In the LC group, in patients with stage III to IV and low and undifferentiated patients, the level of miR-204 was higher than that of stage I∼II and high and moderately differentiated patients, and the difference was statistically significant ( P < 0.001). The level of miR-204 in the two groups of patients (0.89 ± 0.10, 0.83 ± 0.13) who died of illness was significantly higher than that of the surviving patients (1.00 ± 0.11, 1.00 ± 0.10), and the difference was statistically significant ( P < 0.05); the survival rate of patients with high expression of miR-204 was higher than that of patients with low expression. The AUC of serum miR-204 level to SP and LC was 0.766 and 0.818, respectively. Conclusion. The level of miR-204 in the serum of SP patients and patients with primary bronchial LC was significantly lower than that of healthy people, and patients who died were lower than those who survived; the miR-204 in serum has a good diagnostic value for SP and LC and is related to the survival and prognosis of patients.

show abstract

Section: Inclusion Criteria and Exclusionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Study on Serum miR-204 Expression Levels in Patients with Severe Pneumonia and Patients with Primary Bronchial Lung Cancer and Its Diagnostic Value

Zheng¹,

Huang

2021

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

show abstract

“…To further evaluate the effect of lncRNA HEIH on the prognosis of NSCLC, we took the survival of patients as the dependent variable, and included age, smoking, pack-years, tumor diameter, TNM stage, lymph node metastasis, distal metastasis, CEA, comorbidities and LncRNA HEIH as independent variables into Cox multivariate regression analysis model according to the analysis in Table 3 and the possible risk factors affecting the prognosis of NSCLC as previously reported. 32 The results showed that lncRNA HEIH was an independent prognostic risk factor for LUSC patients after adjustment for pack-years and CEA level (P=0.035, HR=9.752, 95% CI: 1.175-80.898); After adjusting for pack-years and CEA level, lncRNA HEIH was an independent prognostic risk factor for LUAD patients (P=0.034, HR=6.623, 95% CI: 1.156-37.950) (Tables 5 and 6).…”

Section: Lncrna Heih Expression Was An Independent Prognostic Risk Fa...mentioning

confidence: 99%

High Expression of lncRNA HEIH is Helpful in the Diagnosis of Non-Small Cell Lung Cancer and Predicts Poor Prognosis

Huang

Yang

et al. 2022

CMAR

View full text Add to dashboard Cite

Background: This study aims to investigate the expression and clinical value of long non-coding RNA (lncRNA) HEIH in peripheral blood of patients with non-small cell lung cancer (NSCLC). Methods: Healthy subjects (N=70), patients with lung squamous cell carcinoma (LUSC, N=70) and patients with lung adenocarcinoma (LUAD, N=80) were included. LncRNA HEIH expression in peripheral blood of included subjects was detected using RT-qPCR. According to the median expression of lncRNA HEIH, LUSC and LUAD patients were allocated into lncRNA HEIH high/low expression groups. The correlation between lncRNA HEIH and clinical indicators of patients was analyzed; Logistic multifactor regression was used to analyze the independent risk factors influencing lncRNA HEIH level. Receiver-operating characteristic (ROC) curve was used to evaluate the diagnostic efficacy of lncRNA HEIH and carcinoembryonic antigen (CEA) in LUSC/LUAD patients. MedCalc-Comparison of ROC curves was used to compare the area under ROC curve. The cumulative survival rates of lncRNA HEIH high/low expression group were analyzed by Kaplan-Meier curve. COX multivariate analysis was used to assess the independent factors affecting prognosis of NSCLC. Results: LncRNA HEIH in peripheral blood of LUSC/LUAD patients was higher than that in healthy controls, with no evident difference between LUSC and LUAD groups. In LUSC/LUAD patients, TNM stage, lymph node metastasis, distal metastasis, and CEA were independent risk factors affecting lncRNA HEIH; patients with high lncRNA HEIH expression had larger pack-years and tumor size, higher CEA level and tumor stage, and higher risk of lymph node metastasis and distal metastasis. LncRNA HEIH had higher diagnostic efficiency than CEA in NSCLC patients. High expression of lncRNA HEIH predicted poor prognosis in patients with NSCLC and was an independent risk factor for prognosis of NSCLC. Conclusion: High expression of lncRNA HEIH is helpful in the diagnosis of NSCLC and predicts poor prognosis.

show abstract

“…Furthermore, it is also known that the relationship of COPD with lung cancer is dependent on the presence of emphysema [76][77][78][79] . Recently, in a cohort of 848 COPD patients followed for an average of 4.3 years (totalling 2858 person-years), the presence of static hyperinflation was identified as an independent risk factor for lung cancer, but not for cancer of any origin 80 .…”

Section: Lung Cancermentioning

confidence: 99%

Lung Hyperinflation in Chronic Obstructive Pulmonary Disease: Clinical and Therapeutic Relevance

García‐Río¹

2021

BRN

Self Cite

View full text Add to dashboard Cite

Patients with chronic obstructive pulmonary disease (COPD) develop lung hyperinflation due to limited expiratory flow, loss of elastic recoil of the lungs or the combination of both, a circumstance that can become intensified during exercise. The increased operating lung volumes, both at rest and during exercise, overload the inspiratory muscles and limit the capacity for lung expansion, resulting in a neuro-mechanical uncoupling that generates or intensifies dyspnoea and limits exercise tolerance. In addition, lung hyperinflation can contribute to cardiovascular dysfunction during exercise and be a risk factor for the development of lung cancer. Bronchodilators are effective for reducing lung hyperinflation, both in static and dynamic situations, and other therapeutic alternatives are also available. In short, lung hyperinflation is a treatable trait of COPD with an important clinical and prognostic impact that requires specific attention.

show abstract

Static lung hyperinflation is an independent risk factor for lung cancer in patients with chronic obstructive pulmonary disease

Cited by 14 publications

References 64 publications

Study on Serum miR-204 Expression Levels in Patients with Severe Pneumonia and Patients with Primary Bronchial Lung Cancer and Its Diagnostic Value

Study on Serum miR-204 Expression Levels in Patients with Severe Pneumonia and Patients with Primary Bronchial Lung Cancer and Its Diagnostic Value

High Expression of lncRNA HEIH is Helpful in the Diagnosis of Non-Small Cell Lung Cancer and Predicts Poor Prognosis

Lung Hyperinflation in Chronic Obstructive Pulmonary Disease: Clinical and Therapeutic Relevance

Contact Info

Product

Resources

About